Health Disparities among Patients with Cancer Who Received Molecular Testing for Biomarker-Directed Therapy.

ABSTRACT: Health disparities present a barrier to successful oncology treatment. The potential for precision oncology to reduce health disparities has not previously been analyzed. We performed a retrospective analysis of 12,627 patients from six major cancer centers whose tumors underwent molecular testing at Caris Life Sciences between 2010 and 2020. Kaplan-Meier and Cox regression were used to describe and analyze overall survival. The molecular and demographic features of the cohort were analyzed by χ2 and ANOVA tests. Black patients composed 25% of the cohort and White patients 63%. Among this molecularly-tested cohort, there were minimal outcome differences based on race, geographic location, or poverty level. When analyzing the interaction of age, race, and sex, racial-based disparities were

SUBMITTER: Heath E 

PROVIDER: S-EPMC11450693 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature